Published in Int J Cardiol on July 15, 2012
Epidemiology of atrial fibrillation: European perspective. Clin Epidemiol (2014) 1.39
Left atrial structure and function in atrial fibrillation: ENGAGE AF-TIMI 48. Eur Heart J (2013) 1.03
Screening for atrial fibrillation with baseline and intermittent ECG recording in an out-of-hospital population. BMC Cardiovasc Disord (2013) 0.94
Atrial fibrillation in women: epidemiology, pathophysiology, presentation, and prognosis. Nat Rev Cardiol (2016) 0.89
Stroke Event Rates and the Optimal Antithrombotic Choice of Patients With Paroxysmal Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Medicine (Baltimore) (2015) 0.75
Effects of body mass index on risks for ischemic stroke, thromboembolism, and mortality in Chinese atrial fibrillation patients: a single-center experience. PLoS One (2015) 0.75
Emerging Tools for Stroke Prevention in Atrial Fibrillation. EBioMedicine (2016) 0.75
Long-term vitamin K antagonists treatment patterns of Non-Valvular Atrial Fibrillation (NVAF): a population-based cohort study. BMC Cardiovasc Disord (2016) 0.75
Atrial fibrillation: the current epidemic. J Geriatr Cardiol (2017) 0.75
Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J (2010) 16.39
A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest (2010) 10.29
Apixaban in patients with atrial fibrillation. N Engl J Med (2011) 9.97
Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med (2012) 6.60
Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J (2006) 6.31
Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace (2010) 6.31
Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT₂R₂ score. Chest (2013) 4.71
Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med (2012) 4.69
Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med (2010) 4.15
Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 4.01
Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited. Lancet (2009) 3.83
Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J (2012) 3.66
Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study. Circulation (2012) 3.47
Is atrial fibrillation an inflammatory disorder? Eur Heart J (2005) 3.33
Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial. BMJ (2007) 3.30
Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. Circulation (2012) 3.30
Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol (2013) 3.13
Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. J Am Coll Cardiol (2013) 3.06
The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study. Ann Rheum Dis (2011) 2.95
Relation of nonsteroidal anti-inflammatory drugs to serious bleeding and thromboembolism risk in patients with atrial fibrillation receiving antithrombotic therapy: a nationwide cohort study. Ann Intern Med (2014) 2.91
The role of aspirin in cardiovascular prevention: implications of aspirin resistance. J Am Coll Cardiol (2008) 2.79
The spectrum of thyroid disease and risk of new onset atrial fibrillation: a large population cohort study. BMJ (2012) 2.65
The adhesion molecule P-selectin and cardiovascular disease. Eur Heart J (2003) 2.57
Anxiety, depression, and prognosis after myocardial infarction: is there a causal association? J Am Coll Cardiol (2003) 2.54
Statins and postoperative risk of atrial fibrillation following coronary artery bypass grafting. Am J Cardiol (2005) 2.47
New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. J Am Coll Cardiol (2012) 2.41
RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. Eur Heart J (2011) 2.40
The global burden of atrial fibrillation and stroke: a systematic review of the epidemiology of atrial fibrillation in regions outside North America and Europe. Chest (2012) 2.33
Role of microRNAs in cardiac remodelling: new insights and future perspectives. Int J Cardiol (2012) 2.32
Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. Thromb Haemost (2014) 2.29
Virchow's triad revisited. South Med J (2004) 2.23
Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost (2011) 2.22
Bridging evidence-based practice and practice-based evidence in periprocedural anticoagulation. Circulation (2012) 2.20
Quality of life in patients with atrial fibrillation: a systematic review. Am J Med (2006) 2.17
Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J (2013) 2.17
Salt intake and Helicobacter pylori infection. J Hypertens (2004) 2.17
Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation (2012) 2.16
Endothelial progenitor cells in cardiovascular disorders. J Am Coll Cardiol (2007) 2.11
Ambulatory blood pressure monitoring in heart failure: a systematic review. Eur J Heart Fail (2005) 2.09
Should we recommend oral anticoagulation therapy in patients with atrial fibrillation undergoing coronary artery stenting with a high HAS-BLED bleeding risk score? Circ Cardiovasc Interv (2012) 2.07
Indications for the use of diagnostic implantable and external ECG loop recorders. Europace (2009) 2.06
Atrial fibrillation. Lancet (2011) 2.05
Prevalence of peripheral artery disease by abnormal ankle-brachial index in atrial fibrillation: implications for risk and therapy. J Am Coll Cardiol (2013) 2.05
Large-scale genomic studies reveal central role of ABO in sP-selectin and sICAM-1 levels. Hum Mol Genet (2010) 2.05
Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study. Thromb Haemost (2011) 2.01
Ischemic stroke in South Asians: a review of the epidemiology, pathophysiology, and ethnicity-related clinical features. Stroke (2009) 1.97
Psychological factors in heart failure: a review of the literature. Arch Intern Med (2002) 1.96
Antithrombotic treatment and the risk of death and stroke in patients with atrial fibrillation and a CHADS2 score=1. Thromb Haemost (2010) 1.96
The hypercoagulable state of malignancy: pathogenesis and current debate. Neoplasia (2002) 1.96
Inflammation in atrial fibrillation. J Am Coll Cardiol (2012) 1.95
Risk of atrial fibrillation and stroke in rheumatoid arthritis: Danish nationwide cohort study. BMJ (2012) 1.94
Asymptomatic hypoxia in a young pregnant lady--unusual presentation of atrial septal defect. Int J Cardiol (2009) 1.92
Outcome parameters for trials in atrial fibrillation: executive summary. Eur Heart J (2007) 1.90
Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis. J Am Coll Cardiol (2008) 1.89
Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J (2006) 1.84
Heparin-induced thrombocytopenia. A contemporary clinical approach to diagnosis and management. Chest (2009) 1.84
The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy. Eur Heart J (2012) 1.82
Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study. Eur Heart J (2009) 1.79
The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study. Thromb Haemost (2012) 1.78
Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial. Lancet Neurol (2012) 1.76
Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) study. Am J Kidney Dis (2004) 1.76
Circulating endothelial cells. Biomarker of vascular disease. Thromb Haemost (2005) 1.73
The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol (2013) 1.72
Volume status and diuretic therapy in systolic heart failure and the detection of early abnormalities in renal and tubular function. J Am Coll Cardiol (2011) 1.70
Patients' understanding of anticoagulant therapy in a multiethnic population. J R Soc Med (2003) 1.69
Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation. Circulation (2010) 1.68
A genome-wide association study identifies two loci associated with heart failure due to dilated cardiomyopathy. Eur Heart J (2011) 1.67
Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fibrillation patients. J Am Coll Cardiol (2011) 1.67
Vascular endothelial growth factor and its receptor, Flt-1, in the plasma of patients with coronary or peripheral atherosclerosis, or Type II diabetes. Clin Sci (Lond) (2002) 1.67
'DNA' may not mean 'did not participate': a qualitative study of reasons for non-adherence at home- and centre-based cardiac rehabilitation. Fam Pract (2007) 1.66
Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study. Circulation (2014) 1.65